Evidence map›Paper›PMID 29982418›Full record

ArticleCardiovascular research2018

α1AMPK deletion in myelomonocytic cells induces a pro-inflammatory phenotype and enhances angiotensin II-induced vascular dysfunction.

Thomas Jansen, Swenja Kröller-Schön, Tanja Schönfelder, Marc Foretz, Benoit Viollet, Andreas Daiber, Matthias Oelze, Moritz Brandt, Sebastian Steven, Miroslava Kvandová and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Cardiovascular research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Sexual Dimorphism in Cardiometabolic Diseases: The Role of AMPK.International journal of molecular sciences · 2023
    Review
  5. Immunometabolism at the Heart of Cardiovascular Disease.JACC. Basic to translational science · 2023
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Adaptive Immunity in Hypertension.Current hypertension reports · 2019
    Review
  12. Review
  13. Stimulation of NaOxidative medicine and cellular longevity · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Thomas JansenDepartment of Cardiology 1, Center for Cardiology, Universitätsmedizin Mainz, Mainz, Germany.
Swenja Kröller-SchönDepartment of Cardiology 1, Center for Cardiology, Universitätsmedizin Mainz, Mainz, Germany.
Tanja SchönfelderCenter for Thrombosis and Hemostasis (CTH), Universitätsmedizin Mainz, Mainz, Germany.
Marc ForetzInstitut Cochin, INSERM U1016, Paris, France.
Benoit ViolletInstitut Cochin, INSERM U1016, Paris, France.
Andreas DaiberDepartment of Cardiology 1, Center for Cardiology, Universitätsmedizin Mainz, Mainz, Germany.
Matthias OelzeDepartment of Cardiology 1, Center for Cardiology, Universitätsmedizin Mainz, Mainz, Germany.
Moritz BrandtDepartment of Cardiology 1, Center for Cardiology, Universitätsmedizin Mainz, Mainz, Germany.
Sebastian StevenDepartment of Cardiology 1, Center for Cardiology, Universitätsmedizin Mainz, Mainz, Germany.
Miroslava KvandováDepartment of Cardiology 1, Center for Cardiology, Universitätsmedizin Mainz, Mainz, Germany.
Sanela KalinovicDepartment of Cardiology 1, Center for Cardiology, Universitätsmedizin Mainz, Mainz, Germany.
Jeremy LagrangeCenter for Thrombosis and Hemostasis (CTH), Universitätsmedizin Mainz, Mainz, Germany.
John F KeaneyDivision of Cardiovascular Medicine, UMass Medical School, 55 Lake Avenue North, Worcester, MA, USA.
Thomas MünzelDepartment of Cardiology 1, Center for Cardiology, Universitätsmedizin Mainz, Mainz, Germany.
Philip WenzelDepartment of Cardiology 1, Center for Cardiology, Universitätsmedizin Mainz, Mainz, Germany.
Eberhard SchulzDepartment of Cardiology 1, Center for Cardiology, Universitätsmedizin Mainz, Mainz, Germany.
Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie · DEJohannes Gutenberg University Mainz · DEDélégation Paris 5 · FRInserm · FRUniversity Medical Center of the Johannes Gutenberg University Mainz · DEUniversity of Massachusetts Chan Medical School · US

Funding

Mitochondrial Modulation of Endothelia FunctionR01HL092122 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KEANEY, JOHN FRANCIS · 2009 to 2016
$3.3M
NHLBI NIH HHS R01 HL092122
6 · The paper itself

Abstract

Aims: Immune cell function involves energy-dependent processes including growth, proliferation, and cytokine production. Since the AMP-activated protein kinase (AMPK) is a crucial regulator of intracellular energy homeostasis, its expression and activity may also affect innate and adaptive immune cell responses. Therefore, we aimed to investigate the consequences of α1AMPK deletion in myelomonocytic cells on vascular function, inflammation, and hypertension during chronic angiotensin II (ATII) treatment. Methods and results: We generated a mouse strain with α1AMPK deletion in lysozyme M+ myelomonocytic cells. Compared to controls, chronic ATII infusion (1 mg/kg/day for 7 days) lead to increased vascular oxidative stress and aggravated endothelial dysfunction in LysM-Cre+ x α1AMPKfl/fl mice. This was accompanied by an increased aortic infiltration of CD11b+F4/80+ macrophages and enhanced pro-inflammatory cytokine release (tumour necrosis factor-alpha, interferon-gamma, and interleukin-6). Mechanistically, we found that increased expression of C-C chemokine receptor 2 (CCR2) in α1AMPK deficient myelomonocytic cells facilitated their recruitment to the vascular wall. In addition, expression of the ATII receptor type 1a and the oxidative burst was increased in these cells, indicating an increased susceptibility towards pro-oxidant stimuli. Conclusions: In summary, α1AMPK deletion in myelomonocytic cells aggravates vascular oxidative stress and dysfunction by enhancing their recruitment to the vascular wall and increasing their susceptibility towards pro-oxidant stimuli. Our observations suggest that metabolic control in myelomonocytic cells has profound implications for their inflammatory phenotype and may trigger the development of vascular disease.

Indexed as

Gene DeletionOxidative StressVasodilationAMP-Activated Protein KinasesAngiotensin IIAnimalsAortaAortic DiseasesCells, CulturedCytokinesDisease Models, AnimalGenetic Predisposition to DiseaseInflammation MediatorsMacrophagesMice, Inbred C57BLMice, KnockoutAMP-Activated Protein KinasesAngiotensin IICytokinesInflammation MediatorsPrkaa1 protein, mouse

Identifiers

PMID29982418
PMCPMC6455900
OpenAlexW2887295758

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.